Statistics on Biotechnology Use  
Results by fields of operation
Company sector. Biotechnology results by main variables and no. of employees. 
Unidades: specified in variables

;Fewer than 250 employees;250 or more employees;Total 2020;
No. of companies carrying out R&D in Biotechnology;1.126;108;1.233;
%Companies according to biotechnology used: Genetic code;30,9;40,2;31,7;
%Companies according to biotechnology used: Functional units;37,4;50,4;38,5;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;21,6;34,5;22,8;
%Companies according to biotechnology used: Bioprocesses;51,7;71;53,4;
%Companies according to biotechnology used: Sub-cellular organisms;7,8;16,8;8,6;
%Companies according to biotechnology used: Bio-computing;22,2;22,3;22,3;
%Companies according to biotechnology used: Nanobiotechnology;10,5;12,1;10,6;
%Companies according to biotechnology used: Other;14,7;9,3;14,2;
Companies in which biotechnology activities are: Main and/or exclusive;590;25;615;
Companies in which biotechnology activities are: A secondary line of business;156;22;178;
Companies in which biotechnology activities are: A tool necessary for production;379;61;440;
%Company by field(s) of ultimate application of biotechnology use: Human Health;46,2;46,5;46,3;
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;16,9;9,3;16,2;
%Company by field(s) of ultimate application of biotechnology use: Food products;31,7;35,6;32;
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production;25,6;14,1;24,6;
%Company by field(s) of ultimate application of biotechnology use: Environment;15,3;17,7;15,5;
%Company by field(s) of ultimate application of biotechnology use: Industry;13,1;11,1;12,9;
Personnel in R&D in biotechnology (no. of persons);9.325;4.119;13.444;
Personnel in R&D in biotechnology (no. of persons): Researchers;5.272;2.106;7.378;
Personnel in R&D in biotechnology (no. of persons): Technicians and assistants;4.053;2.013;6.066;
Personnel in R&D in biotechnology (no. of persons): women;4.869;2.632;7.501;
Personnel in R&D in biotechnology (no. of persons): (women) Researchers;2.752;1.299;4.052;
Personnel in R&D in biotechnology (no. of persons): (women) Technicians and assistants;2.117;1.333;3.450;
Personnel in R&D in biotechnology (FTE);6.291,5;3.110,4;9.401,9;
Personnel in R&D in biotechnology (FTE): Researchers;3.811,8;1.586,5;5.398,3;
Personnel in R&D in biotechnology (FTE): Technicians and assistants;2.479,7;1.523,9;4.003,6;
Personnel in R&D in biotechnology (FTE): women;3.385,8;2.040,5;5.426,2;
Personnel in R&D in biotechnology (FTE): (women) Researchers;2.020,5;996;3.016,4;
Personnel in R&D in biotechnology (FTE): (women) Technicians and assistants;1.365,3;1.044,5;2.409,8;
Internal expenditure on R&D (thousands of euros);586.635;310.698;897.333;
1) By nature of the expense: Current expenses;520.977;296.432;817.409;
1.1) Remuneration to researchers;182.849;112.856;295.705;
1.2) Remuneration to technicians and assistants;90.123;66.730;156.853;
1.3) Other current expenses;248.005;116.847;364.852;
2) By nature of the expense: Capital expenses;65.658;14.266;79.924;
2.1) Land and buildings;6.331;3.941;10.272;
2.2) Equipment and instruments;46.970;9.640;56.609;
2.3) Acquisition of specific R&D software;4.475;364;4.839;
2.4) Otros productos de propiedad intelectual específicos para I+D;7.882;321;8.203;
1.1) By origin of the funds: Own funds;406.605;206.492;613.097;
1.2) By origin of the funds: From companies;62.831;23.253;86.085;
1.3) By origin of the funds: Public Administration funds;71.590;20.550;92.140;
1.4) By origin of the funds: From Universities;548;306;853;
1.5) By origin of the funds: From non profit private institutions;2.496;2.185;4.682;
1.6) By origin of the funds: Foreign funds;42.564;57.912;100.476;
Purchase of R&D services in biotechnology (thousands of euros);48.478;36.533;85.011;
Purchase of R&D services in biotechnology (thousands of euros): In Spain;23.128;31.114;54.243;
Purchase of R&D services in biotechnology (thousands of euros): Abroad;25.350;5.419;30.768;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;40,9;22,4;39,2;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;11,5;14;11,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;12,9;8,4;12,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;10,8;11,2;10,9;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;14,7;10,3;14,3;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels;17,4;7,5;16,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;15,2;13,1;15;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;36;31;36;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;47,2;41;46,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;19,3;15,9;19;
% Companies that have requested biotechnology patents in Biotechnology;17,3;17,7;17,3;
Number of patents requested;600;81;681;
% Companies with income of an international origin related to biotechnological activities;23,6;16,8;23;
% Turnover representing income of an international origin related to biotechnological activities;5,6;0,9;1,6;
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU;44,7;69,7;55,9;
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries;55,3;30,3;44,1;
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services;97,2;67,6;83,9;
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;1,1;31,5;14,7;
% Income of an international origin related with activities according to the classification: Operating source abroad;0,7;0,9;0,8;
% Income of an international origin related with activities according to the classification: Other;1,1;0;0,6;
Notas:
'.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent
Fuente: National Statistics Institute